VA NEPHRON-D: Diabetes iN Nephropathy Study
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Department of Veterans Affairs
First received: November 7, 2007
Last updated: October 20, 2014
Last verified: October 2014
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||October 2014|
|Primary Completion Date:||September 2014 (Final data collection date for primary outcome measure)|
Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P; the VA NEPHRON-D Investigators. Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy. N Engl J Med. 2013 Nov 9. [Epub ahead of print]
Zimering MB, Zhang JH, Guarino PD, Emanuele N, McCullough PA, Fried LF; Investigators for the VA NEPHRON-D. Endothelial cell autoantibodies in predicting declining renal function, end-stage renal disease, or death in adult type 2 diabetic nephropathy. Front Endocrinol (Lausanne). 2014 Aug 11;5:128. doi: 10.3389/fendo.2014.00128. eCollection 2014.